Patent · US Active

Fc containing polypeptides with altered glycosylation and reduced effector function

US10836813B2 · kind B2 · utility

9Cited by
36References
23Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 12, 2017
Grant dateNov 17, 2020
Priority date—
Expiry dateJun 29, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/73
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine or threonine residue at amino acid position 300, according to EU numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.